Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.

Radic, Martina; Vlasic, Ignacija; Jazvinscak Jembrek, Maja; Horvat, Andela; Tadijan, Ana; Sabol, Maja; Duzevic, Marko; Herak Bosnar, Maja; Slade, Neda

Radic, Martina; Vlasic, Ignacija; Jazvinscak Jembrek, Maja; Horvat, Andela; Tadijan, Ana; Sabol, Maja; Duzevic, Marko; Herak Bosnar, Maja; Slade, Neda.

Afiliação

Radic M; Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia.
Vlasic I; Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia.
Jazvinscak Jembrek M; Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia.
Horvat A; School of Medicine, Catholic University of Croatia, 10000 Zagreb, Croatia.
Tadijan A; Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia.
Sabol M; Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia.
Duzevic M; Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruder Boskovic Institute, 10000 Zagreb, Croatia.
Herak Bosnar M; Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia.
Slade N; Laboratory for Protein Dynamics, Division of Molecular Medicine, Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia.

Int J Mol Sci ; 23(17)2022 Aug 31.

Article em En | MEDLINE | ID: mdl-36077308

Assuntos

Melanoma; Proteínas Proto-Oncogênicas B-raf; Linhagem Celular Tumoral; Resistencia a Medicamentos Antineoplásicos/genética; Humanos; Indóis/farmacologia; Indóis/uso terapêutico; Melanoma/tratamento farmacológico; Melanoma/genética; Melanoma/patologia; Fosfatidilinositol 3-Quinases; Proteínas Proto-Oncogênicas B-raf/genética; Proteínas Proto-Oncogênicas B-raf/metabolismo; Proteínas Proto-Oncogênicas c-akt/metabolismo; Sulfonamidas/farmacologia; Sulfonamidas/uso terapêutico; Vemurafenib/farmacologia; Vemurafenib/uso terapêutico

Palavras-chave

NME metastasis suppressor proteins; drug resistance; epithelialmesenchymal transition (EMT); melanoma; signaling pathways; slow-cycling cells; vemurafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article